IP Verse

Pyrrolo[2,3-D]Pyrimidine Derivatives As Janus Kinase Inhibitor - EP3184526

The patent EP3184526 was granted to Incyte on Oct 3, 2018. The application was originally filed on Dec 12, 2006 under application number EP16197502A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3184526

INCYTE
Application Number
EP16197502A
Filing Date
Dec 12, 2006
Status
Granted And Under Opposition
Aug 31, 2018
Grant Date
Oct 3, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

CONCERT PHARMACEUTICALSJun 28, 2019CORNISHWITHDRAWN

Patent Citations (33) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20040578491-
DESCRIPTIONUS2004198737
DESCRIPTIONUS5521184
DESCRIPTIONWO0009495
DESCRIPTIONWO0053595
DESCRIPTIONWO0114402
DESCRIPTIONWO0142246
DESCRIPTIONWO0164655
DESCRIPTIONWO03024967
DESCRIPTIONWO03037347
DESCRIPTIONWO03099771
DESCRIPTIONWO2004005281
DESCRIPTIONWO2004046120
DESCRIPTIONWO2004056786
DESCRIPTIONWO2004072063
DESCRIPTIONWO2004080980
DESCRIPTIONWO2004099204
DESCRIPTIONWO2004099205
DESCRIPTIONWO2005028444
DESCRIPTIONWO2006034833
DESCRIPTIONWO2006056399
DESCRIPTIONWO9962908
DESCRIPTIONWO9965909
SEARCHUS2004009983
SEARCHUS2005153989
SEARCHWO0142246
SEARCHWO0200661
SEARCHWO2004099204
SEARCHWO2004099205
SEARCHWO2005013986
SEARCHWO2006096270
SEARCHWO2006127587
SEARCHWO9965909

Non-Patent Literature (NPL) Citations (38) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ADV PHARMACOL., (2000), vol. 47, pages 113 - 174-
DESCRIPTION- AGENTS ACTIONS, (199301), vol. 38, no. 1-2, pages 116 - 121-
DESCRIPTION- BLUME-JENSEN, P. ET AL., NATURE, (2001), vol. 411, no. 6835, pages 355 - 365-
DESCRIPTION- BOLEN JB, "Nonreceptor tyrosine protein kinases", ONCOGENE, (1993), vol. 8, no. 8, pages 2025 - 2031-
DESCRIPTION- BOUDNY, V.; KOVARIK, J., NEOPLASM, (2002), vol. 49, pages 349 - 355-
DESCRIPTION- BOWMAN, T. ET AL., ONCOGENE, (2000), vol. 19, pages 2474 - 2488-
DESCRIPTION- BURGER, R. ET AL., HEMATOL J., (2001), vol. 2, pages 42 - 53-
DESCRIPTION- CANDOTTI, F.; L. NOTARANGELO ET AL., "Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways", J CLIN INVEST, (2002), vol. 109, no. 10, pages 1261 - 1269-
DESCRIPTION- CANDOTTI, F.; S. A. OAKES ET AL., "Structural and functional basis for JAK3-deficient severe combined immunodeficiency", BLOOD, (1997), vol. 90, no. 10, pages 3996 - 4003-
DESCRIPTION- CETKOVIC-CVRLJE, M.; A. L. DRAGT ET AL., "Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice", CLIN IMMUNOL, (2003), vol. 106, no. 3, pages 213 - 225-
DESCRIPTION- COLIGAN, J.E. ET AL., Current Protocols in Immunology, WILEY PRESS., vol. 3-
DESCRIPTION- DE VOS, J.; M. JOURDAN ET AL., "JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells", BR JHAEMATOL, (2000), vol. 109, no. 4, pages 823 - 828-
DESCRIPTION- DUDLEY, A.C. ET AL., BIOCHEM. J., (2005), vol. 390, pages 427 - 436-
DESCRIPTION- E. QUESADA ET AL., TETRAHEDRON, (2006), vol. 62, pages 6673 - 6680-
DESCRIPTION- GOTTLIEB, A.B. ET AL., NAT REV DRUG DISC., vol. 4, pages 19 - 34-
DESCRIPTION- IMMUNOL TODAY, (199801), vol. 19, no. L, pages 37 - 44-
DESCRIPTION- JAMES, C. ET AL., NATURE, vol. 434, pages 1144 - 1148-
DESCRIPTION- JCI, vol. 113, pages 1664 - 1675-
DESCRIPTION- JOURNAL OF PHARMACEUTICAL SCIENCE, (1977), vol. 66, page 2-
DESCRIPTION- KAWAMURA, M.; D. W. MCVICAR ET AL., "Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes", PROC NATL ACAD SCI USA, (1994), vol. 91, no. 14, pages 6374 - 6378-
DESCRIPTION- LEVIN ET AL., CANCER CELL, (2005), vol. 7, pages 387 - 397-
DESCRIPTION- MADHUSUDAN S; GANESAN TS, "Tyrosine kinase inhibitors in cancer therapy", CLIN BIOCHEM., (2004), vol. 37, no. 7, pages 618 - 635-
DESCRIPTION- MANNING, G. ET AL., SCIENCE, (2002), vol. 298, no. 5600, pages 1912 - 1934-
DESCRIPTION- "Methods in Molecular Biology", WINYARD, P.G.; WILLOUGHBY, D.A., Inflammation Protocols., HUMANA PRESS, (2003), vol. 225-
DESCRIPTION- NEUBAUER, H.; A. CUMANO ET AL., CELL, (1998), vol. 93, no. 3, pages 397 - 409-
DESCRIPTION- ORTMANN, R. A.; T. CHENG ET AL., "Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation", ARTHRITIS RES, (2000), vol. 2, no. 1, pages 16 - 32-
DESCRIPTION- PARGANAS, E.; D. WANG ET AL., CELL, (1998), vol. 93, no. 3, pages 385 - 395-
DESCRIPTION- PARK ET AL., ANALYTICAL BIOCHEMISTRY, (1999), vol. 269, pages 94 - 104-
DESCRIPTION- PERNIS, A. B.; P. B. ROTHMAN, "JAK-STAT signaling in asthma", J CLIN INVEST, (2002), vol. 109, no. 10, pages 1279 - 1283-
DESCRIPTION- Remington's Pharmaceutical Sciences, MACK- PUBLISHING COMPANY, EASTON, PA., (1985), page 1418-
DESCRIPTION- RODIG, S. J.; M. A. MERAZ ET AL., "Disruption of the Jakl gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses", CELL, (1998), vol. 93, no. 3, pages 373 - 383-
DESCRIPTION- SAEMANN, M. D.; C. DIAKOS ET AL., "Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3", AM J TRANSPLANT, (2003), vol. 3, no. 11, pages 1341 - 1349-
DESCRIPTION- SCOTT, M. J.; C. J. GODSHALL ET AL., "Jaks, STATs, Cytokines, and Sepsis", CLIN DIAGN LAB IMMUNOL, (2002), vol. 9, no. 6, pages 1153 - 1159-
DESCRIPTION- SETO, Y.; H. NAKAJIMA ET AL., "Enhanced Th2 cell-mediated allergic inflammation in Tyk2-deficient mice", J IMMUNOL, (2003), vol. 170, no. 2, pages 1077 - 1083-
DESCRIPTION- SRIRAM, K. ET AL., J. BIOL. CHEM. 2004, (20040302), vol. 279, no. 19, pages 19936 - 19947-
DESCRIPTION- STAERK, J. ET AL., JBC, vol. 280, pages 41893 - 41899-
DESCRIPTION- TAKEMOTO, S.; J. C. MULLOY ET AL., "Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins", PROC NATL ACAD SCI U S A, (1997), vol. 94, no. 25, pages 13897 - 13902-
DESCRIPTION- T. HIGUCHI; V. STELLA, Pro-drugs as Novel Delivery Systems, A.C.S. SYMPOSIUM SERIES, vol. 14-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents